These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 18399831)
1. A novel murine model of allogeneic vaccination against renal cancer. Havranek EG; Labarthe MC; Ward S; Anderson CJ; Whelan MA; Pandha H BJU Int; 2008 May; 101(9):1165-9. PubMed ID: 18399831 [TBL] [Abstract][Full Text] [Related]
2. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity. Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300 [TBL] [Abstract][Full Text] [Related]
4. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. Fujioka T; Hasegawa M; Ishikura K; Matsushita Y; Sato M; Tanji S J Urol; 1998 Jul; 160(1):247-51. PubMed ID: 9628658 [TBL] [Abstract][Full Text] [Related]
6. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988 [TBL] [Abstract][Full Text] [Related]
7. Vaccine therapy in patients with renal cell carcinoma. Van Poppel H; Joniau S; Van Gool SW Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522 [TBL] [Abstract][Full Text] [Related]
8. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cho JA; Lee YS; Kim SH; Ko JK; Kim CW Cancer Lett; 2009 Mar; 275(2):256-65. PubMed ID: 19036499 [TBL] [Abstract][Full Text] [Related]
9. Whole tumor cell vaccine with irradiated S180 cells as adjuvant. Li J; King AV; Stickel SL; Burgin KE; Zhang X; Wagner TE; Wei Y Vaccine; 2009 Jan; 27(4):558-64. PubMed ID: 19027812 [TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Mulders P Eur Urol; 2009 Jul; 56(1):132-3. PubMed ID: 18550266 [No Abstract] [Full Text] [Related]
13. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534 [TBL] [Abstract][Full Text] [Related]
14. Cell based cancer vaccines: regulatory and commercial development. Copier J; Ward S; Dalgleish A Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462 [TBL] [Abstract][Full Text] [Related]
15. Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Novara G Eur Urol; 2009 Jul; 56(1):131-2. PubMed ID: 18550268 [No Abstract] [Full Text] [Related]
16. Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases. Fifis T; Lam I; Lin D; Malcontenti-Wilson C; Christophi C; Loveland B Vaccine; 2008 Jan; 26(2):241-9. PubMed ID: 18069095 [TBL] [Abstract][Full Text] [Related]
17. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Bolhassani A; Zahedifard F; Taghikhani M; Rafati S Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945 [TBL] [Abstract][Full Text] [Related]
18. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. Bird RC; Deinnocentes P; Lenz S; Thacker EE; Curiel DT; Smith BF Vet Immunol Immunopathol; 2008 Jun; 123(3-4):289-304. PubMed ID: 18423623 [TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of human renal cancer cell lines and autologous normal kidney short term cultures. Schattka S; Decken K; Schmitz-Dräger B; Ackermann R; Ebert T Investig Urol (Berl); 1994; 5():35-41. PubMed ID: 7719318 [No Abstract] [Full Text] [Related]
20. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Kim S; Lee JB; Lee GK; Chang J Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]